|
注册号: Registration number: |
ChiCTR2500109131 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-12 10:37:11 |
|
注册时间: Date of Registration: |
2025-09-12 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
脑白质发育异常早产儿及远期脑智功能的追踪队列研究 |
|
Public title: |
Cohort research for follow-up on preterm white matter abnormalities and long-term brain function |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脑白质发育异常早产儿及其远期脑智功能的追踪队列研究 |
|
Scientific title: |
Cohort research for follow-up on preterm white matter abnormalities and long-term brain function |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
彭文杰 |
研究负责人: |
胡章雪 |
|
Applicant: |
Wenjie Peng |
Study leader: |
Zhangxue Hu |
|
申请注册联系人电话: Applicant telephone: |
+86 135 0034 5707 |
研究负责人电话:
Study leader's |
+86 186 9666 8598 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
pengwenjie@tmmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
huzhangxue@tmmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区大坪长江支路10号 |
研究负责人通讯地址: |
重庆市渝中区大坪长江支路10号 |
|
Applicant address: |
10 Changjiang Branch Road, Daping, Yuzhong District, Chongqing |
Study leader's address: |
10 Changjiang Branch Road, Daping, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军陆军特色医学中心 |
||
|
Applicant's institution: |
Army Medical Center of PLA |
||
|
研究负责人所在单位: |
中国人民解放军陆军特色医学中心 |
||
|
Affiliation of the Leader: |
Army Medical Center of PLA |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
医研伦审(2022)第 123 号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军特色医学中心伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Army Medical Center of PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-04-26 00:00:00 | ||
|
伦理委员会联系人: |
王晶晶 |
||
|
Contact Name of the ethic committee: |
Jingjing Wang |
||
|
伦理委员会联系地址: |
重庆市渝中区大坪长江支路10号 |
||
|
Contact Address of the ethic committee: |
10 Changjiang Branch Road, Daping, Yuzhong District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 6875 7140 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
wii1017@163.com |
|
研究实施负责(组长)单位: |
中国人民解放军陆军特色医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Army Medical Center of PLA |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区大坪长江支路10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
10 Changjiang Branch Road, Daping, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中央财政 |
||||||||||||||||||||||
|
Source(s) of funding: |
Central finance |
||||||||||||||||||||||
|
研究疾病: |
早产儿脑白质异常 |
||||||||||||||||||||||
|
Target disease: |
White matter abnormality of prmaturity |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本课题旨在解析脑白质发育异常在预测儿童高级认知功能障碍中的作用,发,展基于脑白质异常发育模式预测儿童远期脑智功能的模型和方法,实现针对儿童智力障碍的早期预警。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study analyze the role of abnormal white matter development in predicting children's advanced cognitive dysfunction, and seeks to create models and methods for predicting children's long-term cerebral and intellectual function based on abnormal white matter development patterns, as well as to achieve early warning of children's intellectual disability. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.神经系统肿瘤; 2.合并严重畸形、严重心、肺、肝、肾功能障碍者和患有威胁生命的疾病或严重不稳定的潜在疾病的患者,如严重呼吸系统疾病、心脑血管疾病、消化系统疾病、内分泌系统疾病、泌尿系统疾病、凝血功能障碍、遗传代谢病等; 3.不适用于MRI检查,例如由于体内留有不兼容的植入物; 4.正参加其它临床试验的患者; 5.研究人员认为其他原因不适合入组或影响受试者参与完成研究的其他因素。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Nervous system tumors; 2. Patients with severe malformations, severe heart, lung, liver, kidney dysfunction, and patients with life-threatening diseases or serious unstable potential diseases, such as severe respiratory diseases, cardiovascular and cerebrovascular diseases, digestive diseases, endocrine diseases, urinary system diseases, coagulation disorders, inherited metabolic diseases, etc. 3. not suitable for MRI examination, e.g. due to incompatible implants left in the body; 4. Patients enrolled in other clinical trials; 5. Other reasons considered by the researcher to be unsuitable for enrollment or other factors affecting the participant's participation in completing the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-05-01 00:00:00至 To 2026-11-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-10-31 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |